In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Cyclacel in-licenses novel anticancer drug from Lorus Therapeutics
Cyclacel announces in-licensing of phase I anticancer drug from Sankyo
LORUS SIGNS AGREEMENT WITH JAPAN'S SUMITOMO PHARMACEUTICALS AND KOKEN CO. LTD
Cyclacel and Xcyte Therapies combine to form international biopharmaceutical company
Lorus to conduct clinicals on lead antisense drug
CYCLACEL AND ALTANA PHARMA ANNOUNCE COLLABORATION ON MITOTIC TARGET IDENTIFICATION
CYCLACEL ANNOUNCES COLLABORATION ON NEPHROLOGY APPLICATIONS OF CDK INHIBITORS